Smart syringes are medical devices designed with safety features to prevent using syringes again and control unsafe injections. These syringes are designed to prevent needlestick injuries and the spread of bloodborne diseases like hepatitis C virus, hepatitis B viruses (HBV), or human immunodeficiency virus (HIV). These syringes can be used for many purposes, including drug delivery, vaccination, and collection of blood samples. There are three types of smart syringes: active safety, passive safety, and auto-disable (AD). Each type is used according to the Application. Active safety syringes and auto-disable (AD syringes) are the most commonly used smart syringes across all healthcare sectors.
Global smart syringe markets were valued at $6,870.19 million in 2019. They are expected to grow to $14,185.45million by 2027. This represents an 8.7% CAGR over the forecast period. Market growth is driven by increased needle stick injuries, a high prevalence of bloodborne diseases such as HIV and hepatitis B/C, and improper injection practices. There has also been an increase in the adoption of safety syringes and technological advancements. Market growth is also aided by mandatory WHO recommendations to switch to smart Syringes. This ensures safe injection practices. The market growth will be impeded by the high cost of smart syringes (especially passive safety syringes), low awareness in developing countries, and other drug delivery methods. Global smart syringe sales are expected to exceed 28,078.73 million units by 2027 and grow at an 8.9% CAGR over the forecast period.
The COVID-19 vaccination programs, which are planned worldwide, will significantly increase smart syringes being used over the next few years. Infected with COVID-19, the virus has already been proven to cause shortages in medical equipment, such as the supply of gowns and face masks. Governments and other organizations have begun syringe production and manufacturing to overcome these supply chain problems since they are an essential component of vaccine delivery. Smart syringe manufacturing will be able to meet the global demand for vaccines against novel coronavirus throughout the pandemic phase.
Product Segment Review
You can categorize the product segment into active safety syringes (passive safety syringes), auto-disable (AD), and safety syringes. Due to its established market position, the active safety segment of syringes accounted for the largest revenue in 2019. Auto disables (AD), syringes that are specifically designed for vaccination purposes, are embedded with an internal mechanism that blocks the barrel and prevents it from being used again. Many companies worldwide are producing safety syringes as countries prepare for the coronavirus vaccine. In August 2020, Hindustan Syringes & Medical Devices Ltd. (HMD) confirmed that it had received a 140 million order for COVID-19 auto-disable syringes from UNICEF. The company expects to increase its AD syringes production to 1 billion in the first half of 2021. These factors are expected to increase the growth of the smart-syringe market during the forecast period.
Application Segment Review
Smart syringes can be used for various purposes, including drug delivery, vaccination, and collection of blood specimens. The drug delivery segment is the most popular due to its many applications in therapeutics. Syringes are used extensively in drug delivery to administer therapeutic drugs (therapeutic) to patients. Injections are a preferred method of drug delivery because they allow for good absorption. Injections are more efficient than oral delivery, have a shorter onset time, and allow precise titration. The smart syringe market is expected to grow through product launches by pharmaceutical companies for effective vaccination. Sharps Technology, Inc. launched the smart safety syringe SHARPS PROVENCE in July 2020 amid the COVID-19 pandemic. It expects to begin production in the fourth quarter of 2020.
Age Group Segment Review
The smart syringe market can be divided into two groups based on age: adults and children. The highest CAGR at 9.8% is in the pediatric market. This is due to the increase in the number of children between 0-18 years old, who are more susceptible to transmission of infections. Unsafe disposable syringes led to more than 200 HIV-positive children and adults in Cambodia in 2014. In 2015, the WHO declared that all hospitals and clinics should be using smart syringes by 2020. This initiative is expected to boost market growth by increasing healthcare providers’ demand for smart needles. The COVID-19 pandemic, which is more likely to affect adults over 60, will increase the demand for smart needles. They are more vulnerable to infection and at greater risk. In the future, government initiatives to immunize high-risk groups every year are expected to increase the growth of the adult population.
End-User Section Review
It is divided by end-user into hospitals & HMOs, diabetic patients, family practices, and psychiatrists. Smart syringes are used most often by hospitals and HMOs to deliver drugs, collect blood samples, and administer vaccinations. Smart syringes are used by hospitals such as the Mayo Clinic and Johns Hopkins Hospitals, UCLA Medical Center, Cleveland Clinic, and UCLA Medical Center. These hospitals adopted smart syringes late but recently mandated their use after following the WHO recommendations to prevent needle-sick injuries. HMOs and hospitals are also working with distributors and manufacturers of smart syringes.
Region segment review
In 2019, North America held the largest market share in smart syringes, followed by Europe and Asia-Pacific. It held 42.3% of the market share. This was due to the large adoption of safety syringes due to increased awareness about needle stick injuries and continuous improvements in healthcare practices at healthcare centers throughout the Region. Asia-Pacific is expected to grow at the highest CAGR rate over the forecast period. This is due to increased healthcare spending and a greater awareness of the dangers of using syringes in unsafe ways.
Key Benefits for Stakeholders
- This report presents a quantitative analysis of smart syringe market trends and forecast estimations for 2019 to 2027 and helps identify market opportunities.
- A comprehensive smart syringe market study includes an analysis of different regions. This is expected to give stakeholders a clear understanding of current trends and enable them to formulate region-specific plans.
- This report provides a comprehensive analysis of the factors that have influenced and resisted the growth of smart syringe markets worldwide.
- This report comprehensively analyzes the smart syringe market conditions in each region and country.
- This report analyzes current trends and future smart-syringe market value from 2020 to 2027.
- Companies can use the insights from a thorough analysis of different regions to strategically plan their business moves.
- This report profiles key market players in the smart syringe industry and analyzes their strategies thoroughly. This helps to understand the global smart syringe market’s competitive outlook.
Smart Syringe Market Report Scope and Segmentation
|UNIT||Value (USD Million/Billion)|
|BY REGION||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
Key Market Segments
- Auto Disable Syringes
- Active Safety Syringes
- Passive Safety Syringes
- Drug Delivery
- Blood Specimens Collection
By Age Group
- Hospitals & HMOs
- Diabetic patients
- Family practices (Physicians).
- North America
- The Netherlands
- Czech Republic
- Rest of Europe
- Asia Pacific
- South Korea
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- South Africa
- Northern Africa
- Rest of MEA
- North America
Key Market Participants
- B. BRAUN MELSUNGEN AB
- BECTON, DICKINSON, AND COMPANY
- CARDINAL HEATHEALTH, INC.
- GERRESHEIMER AGENCY
- MERIT MEDICAL SYTEMS, INC.
- NIPRO CORPORATION
- RETRACTABLETECHNOLOGIES INC.
- REVOLUTIONS MEDICINE CORPORATION
- SMITHS GROUP PLC.
- TERUMO CORPORATION